Shares of Veru Inc. VERU were up 20% after it announced on Monday that the FDA had granted Fast Track designation to the phase III registration study on its breast cancer candidate, enobosarm. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback